Abstract
The novel human coronavirus 2 (SARS-CoV-2) is responsible for the COVID-19 outbreak, which reached pandemic-level infection rates in just a few short months after being identified in late 2019. Early transmission models focused on surface contamination, but current research provides evidence for person-to-person transmission via aerosolized viral particles. As such, the CDC’s guidance has recently been updated to increasingly redirect the focus of prevention methods to aerosol routes. Inhalation of SARS-CoV-2 particles presents the most significant threat of infection to individuals. A secondary route, from hand to mouth, eyes or nose, is likely after contact with a surface contaminated with particles that have settled out of aerosols or been deposited by contaminated hands. Using common molecular detection methods including endpoint and quantitative PCR, we investigated whether there is detectable contamination by SARS-CoV-2 on high-touch surfaces on public transit vehicles and on other high-touch surfaces on a college campus during normal use. Our results indicate that SARS-CoV-2 can be successfully recovered and detected on common high-touch surfaces, albeit in comparatively lower frequencies as public health guidance progressed and more rigorous sanitization procedures were implemented.
Graphical abstract created with permission from BioRender.com (2021).
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This research was supported by the University of North Carolina Office of Research and Economic Development.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
UNC Charlotte Institutional Review Board
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data is presented in supplementary files included in this submission.
